Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
20.05.2025 07:14:40
|
Press Release: Basilea announces commercial -2-
Staphylococcus aureus bacteremia (SAB) is a serious bloodstream infection associated with significant morbidity and mortality.(3) Complications include concomitant infections such as bone, joint or heart valve infections, persistent bacteremia or bacteremia in patients on dialysis. With a 30-day all-cause mortality of around 20% there is a high medical need for improved therapies for SAB.(4)
About acute bacterial skin and skin structure infections (ABSSSI)
Acute bacterial skin and skin structure infections (ABSSSI) are common infections in the healthcare setting. Staphylococcus aureus is the most common pathogen associated with these infections, which can be difficult to treat if methicillin-resistant Staphylococcus aureus (MRSA) is involved.(5)
About community-acquired bacterial pneumonia (CABP)
Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality worldwide. It is the leading cause of infectious disease-related death in the US.(6)
About Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO(R) (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA(R) (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA(R) (eravacycline) for the treatment of complicated intra-abdominal infections in adults. On December 14, 2024, Innoviva entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil for the commercialization of ZEVTERA(R) (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the US.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit https://www.globenewswire.com/Tracker?data=eCELRpczWizrA4g7urCtCESdOCmrz-GNdcIYr0nNdlmtLSZUZ_ZYF8ETqjSWvCAWDPU80aM1J-EiU2aeEemS7Q== basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com
This press release can be downloaded from www.basilea.com.
References
1. Summary of Product Characteristics (SmPC) Zevtera:
https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: May 19,
2025]
2. Full US prescribing information:
https://innovivaspecialtytherapeutics.com/wp-content/uploads/2025/05/Prescribing-Information-Zevtera.pdf
[Accessed: May 19, 2025]
3. A. P. Kourtis, K. Hatfield, J. Baggs et al. Vital signs: Epidemiology and
recent trends in methicillin-resistant and in methicillin-susceptible
Staphylococcus aureus bloodstream infections -- United States. Morbidity
and Mortality Weekly Report 2019 (68), 214-219
4. K. Hamed, M. Engelhardt, M. E. Jones et al. Ceftobiprole versus
daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a
double-blind, Phase III trial. Future Microbiology 2020 (1), 35-48
5. J. Edelsberg, C. Taneja, M. Zervos et al. Trends in US hospital
admissions for skin and soft tissue infections. Emerging Infectious
Diseases 2009 (15), 1516-1518
6. J. A. Ramirez, T. L. Wiemken, P. Peyrani et al. Adults hospitalized with
pneumonia in the United States: Incidence, epidemiology, and mortality.
Clinical Infectious Diseases 2017 (65), 1807-1812
Attachment
-- Press release (PDF)
https://ml-eu.globenewswire.com/Resource/Download/a7a96be2-bdd4-477a-8f76-3266f43ae642
(END) Dow Jones Newswires
May 20, 2025 01:15 ET (05:15 GMT)
Nachrichten zu Basilea Pharmaceutica AG
Analysen zu Basilea Pharmaceutica AG
Was passiert, wenn ein schlankes Fintech mit einer klaren Mission den Schweizer Vorsorgemarkt aufrollt?
Im aktuellen BX Morningcalls begrüssen wir Beat Bühlmann, Präsident des Verwaltungsrates von finpension – einem spannenden Fintechs im Schweizer Vorsorgemarkt.
Seit seiner Gründung 2016 hat finpension ein beeindruckendes Wachstum hingelegt: Über 3 Milliarden Franken verwaltetes Vermögen, mehr als 35’000 Kunden – und das mit einem kleinen, hochspezialisierten Team.
Doch was steckt wirklich hinter dieser Erfolgsstory? Und wohin geht die Reise?
Im Gespräch mit François Bloch und Olivia Hähnel (BX Swiss) erklärt Beat Bühlmann, warum traditionelle Banken unter Druck geraten, wie man mit nur 1 Franken in Private Equity investieren kann – und weshalb Technologie, Transparenz und Unabhängigkeit die Säulen moderner Vorsorge sein müssen.
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Sorge um mögliche Eskalation des Nahostkrieges: SMI nach SNB-Zinsentscheid im Minus -- DAX leichter -- US-Börsen mit Feiertagspause -- Asiens Börsen schliessen schwachDer heimische und der deutsche Aktienmarkt fuhren am Donnerstag Verluste ein. Die wichtigsten Börsen in Asien gaben am Donnerstag klar nach. In den USA wird am Donnerstag aufgrund eines Feiertages nicht gehandelt.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |